Trulieve Cannabis Corp Dossier - Source-backed chat

Trulieve Cannabis Corp

TRLVNYSE

SectorHealth Care

IndustryDrug Manufacturers - Specialty & Generic

Beta (adjusted)1.47

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.90Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $2.1B

Enterprise Value $2B

Shares Outstanding 192.8M diluted

Moat Rating None

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Trulieve Cannabis Corp. represents a compelling investment opportunity in the U.S. cannabis sector, driven by its historic uplisting to the NYSE on June 10, 2026, and the federal rescheduling of medical marijuana to Schedule III. As the largest U.S. medical marijuana operator, Trulieve is uniquely positioned to benefit from the elimination of the punitive IRS 280E tax burden, which will dramatically improve its cash flow and profitability. The company's strong balance sheet, robust retail footprint of over 200 dispensaries, and disciplined vertical integration model provide a solid foundation for scaling operations in high-potential markets like Florida, Georgia, Pennsylvania, and Texas.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$15.00

Mean target$18.18

High · most bullish analyst$21.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$15.00

Prolonged regulatory delays in federal rescheduling implementation, persistent pricing pressures in mature markets, failure to resolve the 280E tax challenge favorably, or slower-than-expected market adoption in Georgia and Texas. These factors could constrain valuation multiples and delay the path to consistent GAAP net profitability.

Base CaseCentral scenario

$18.18

Matches the consensus mean

Steady execution of the medical-only strategy in core states, gradual realization of 280E tax relief under Schedule III, and moderate retail expansion. The company maintains its industry-leading gross margins (~60%) and positive adjusted EBITDA, supported by a growing loyalty program of over 1 million members.

Bull CaseUpside scenario

$21.00

Accelerated federal reform, successful resolution of the $523 million 280E tax challenge resulting in substantial cash refunds, rapid adult-use legalization in Florida, and successful expansion of pharmacy distribution in Georgia and Texas. These catalysts would drive significant multiple expansion and institutional capital inflows following the NYSE uplisting.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First U.S. cannabis operator to uplist to the NYSE (ticker: TRLV), unlocking access to a vast pool of institutional liquidity.
Rescheduling of medical marijuana to Schedule III removes the 280E tax burden, significantly boosting net income and cash generation.
Dominant market position as the largest U.S. medical cannabis operator with 206 dispensaries and 3.5 million sq. ft. of cultivation capacity.
Strong financial profile with $353 million in cash as of Q1 2026 and a proven track record of positive operating cash flow.

Key Investment Risks

Regulatory volatility and potential delays in the federal rulemaking and DEA registration processes.
Uncertainty surrounding the ultimate resolution of the $523 million historical 280E tax challenge.
Intense competition and pricing compression in key markets like Florida and Pennsylvania.

Thesis Invalidation Triggers

Reversal or significant delay of the federal Schedule III rescheduling implementation.
Adverse ruling in the IRS 280E tax challenge forcing substantial cash outflows.
Severe margin compression below 50% due to irrational pricing competition.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.